Clinical trials: Advanced Digestive System Carcinoma
Carcinoma, Pancreatic Ductal
Efficacy Study of Gemcitabine, Paclitaxel, and Irradiation in the Treatment of Pancreatic Cancer
The purpose of this study is to find out what effects, good and bad, the chemotherapy drugs gemcitabine (Gemzar) and paclitaxel (Taxol) have in combination with twice daily radiation treatment on locally advanced pancreatic…
- Trial name
- NCT00226746
- Testing
- Paclitaxel and gemcitabine
- Where
- United States
- Sponsor
- New York Presbyterian Brooklyn Methodist Hospital
Esophageal Cancer
Pembrolizumab Combined With Preoperative Chemotherapy (Albumin Paclitaxel+Carboplatin) Neoadjuvant Therapy for Resectable Locally Advanced (Stage II/III) Esophageal Squamous Cell Carcinoma
This study is a prospective, single center, open label, single arm clinical study. Select resectable locally advanced (cT3-4aN0M0, cT1-3N1-2M0, cII/III stage) esophageal cancer with pathological diagnosis of squamous cell…
- Trial name
- NCT06304350
- Testing
- Combination of pembrolizumab and platinum containing dual drugs
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Tongji University
Metastatic Colorectal Cancer
Trifluridine/Tipiracil (TAS-102) With or Without Thalidomide for the Treatment of Metastatic Colorectal Cancer
Thalidomide has both anti-angiogenesis and antiemetic effects, and its combined use with TAS-102 may reduce the gastrointestinal reactions associated with TAS-102, while enhancing antitumor efficacy and reducing the side effects…
- Trial name
- NCT05266820
- Testing
- Thalidomide, TAS-102
- Where
- 6 sites in China
- Volunteers
- 120 people
- Sponsor
- Fujian Cancer Hospital
Cancer, Sarcoma
EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
This Phase 1/2 study evaluates the safety, tolerability, and preliminary anti-tumor activity of EBNK-001 (allogeneic NK cells) given after lymphodepleting cyclophosphamide/fludarabine (CY/FLU) and supported with low-dose IL-15…
- Conditions
- Cancer, Sarcoma, Leukaemia, Breast Cancer (Locally Advanced or Metastatic)
- Trial name
- EBNK-ST-001 (NCT07410676)
- Testing
- EBNK-001 + IL-15 + Pembrolizumab
- Where
- China
- Volunteers
- 83 people
- Sponsor
- Essen Biotech
Hepatocellular Carcinoma
Efficacy and Safety Study of TLC388 to Advanced Hepatocellular Carcinoma
The purpose of this study is to evaluate the safety and efficacy of TLC388 (Lipotecan) as a second line treatment in subjects with advanced Hepatocellular Carcinoma.
- Trial name
- NCT02267213
- Testing
- Lipotecan
- Where
- 12 sites in China, Taiwan
- Volunteers
- 29 people
- Sponsor
- Taiwan Liposome Company
Non Small Cell Lung Cancer, Hepatocellular Carcinoma
Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types
This is a Phase 1, open-label, dose escalation and expansion study of MT-8421 (an Engineered Toxin Body (ETB)) as monotherapy and in combination with nivolumab in patients with selected advanced solid cancer types.
- Conditions
- Non Small Cell Lung Cancer, Hepatocellular Carcinoma, Melanoma, Renal Cell Carcinoma
- Trial name
- NCT06034860
- Testing
- MT-8421, Nivolumab
- Where
- 5 sites in United States
- Volunteers
- 15 people
- Sponsor
- Molecular Templates, Inc.
Liver Cancer
Nolatrexed Dihydrochloride Compared With Doxorubicin in Treating Patients With Recurrent or Unresectable Liver Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which chemotherapy regimen is more effective for liver cancer.
- Trial name
- NCT00012324
- Testing
- doxorubicin hydrochloride, nolatrexed dihydrochloride
- Where
- 42 sites in United States, Canada and 1 more
- Sponsor
- Eximias Pharmaceutical
Advanced Hepatocellular Carcinoma
Evaluation of the Efficacy of Long-acting Release Octreotide in Patients With Advanced Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is one of the most common malignant disease worldwide with an increasing incidence in industrialized countries. For patients with advanced HCC no efficient treatment is currently available.
- Trial name
- NCT00241020
- Testing
- Octreotide
- Volunteers
- 270 people
- Sponsor
- Novartis Pharmaceuticals
Hepatocellular Carcinoma
Study of Sorafenib and Gemcitabine in Advanced Hepatocellular Carcinoma (HCC)
For the majority of patients, metastatic HCC is incurable and patients should be considered candidates for clinical trials when appropriate.
- Trial name
- HCC (NCT00844688)
- Testing
- sorafenib, Gemcitabine
- Where
- Pakistan
- Volunteers
- 30 people
- Sponsor
- Combined Military Hospital, Pakistan
Esophageal Squamous Cell Carcinoma (ESCC)
QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma
This study is designed to assess the efficacy and safety of QLC5508 in patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) who have experienced disease progression following treatment with…
- Trial name
- NCT07463573
- Testing
- QLC5508, Investigator's Choice of Chemotherapy (docetaxel, paclitaxel, or Irinotecan Hydrochloride)
- Where
- China
- Volunteers
- 466 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Adult Primary Cholangiocellular Carcinoma, Adult Primary Hepatocellular Carcinoma
Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer
Phase II trial to study the effectiveness of erlotinib in treating patients who have unresectable liver, bile duct, or gallbladder cancer.
- Conditions
- Adult Primary Cholangiocellular Carcinoma, Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Cholangiocarcinoma of the Extrahepatic Bile Duct
- Trial name
- NCT00033462
- Testing
- erlotinib hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumors
A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors
This is a study of BMS-986490 as a monotherapy and in combination with bevacizumab in participants with select advanced solid tumors known to express CEACAM5.
- Trial name
- NCT06730750
- Testing
- BMS-986490, Bevacizumab
- Where
- 6 sites in United States, Australia and 1 more
- Volunteers
- 360 people
- Sponsor
- Bristol-Myers Squibb
HER2 Positive Gastric Cancer, Colorectal Cancer
FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors
This is a Phase 1, single-dose, open-label, dose-escalation study. The study will be conducted in three parts (i.e. regimens) in an outpatient setting as follows: Regimen A: FATE-NK100 as a monotherapy in subjects with advanced…
- Conditions
- HER2 Positive Gastric Cancer, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, EGFR Positive Solid Tumor
- Trial name
- NCT03319459
- Testing
- FATE-NK100, Cetuximab, Trastuzumab
- Where
- 4 sites in United States
- Volunteers
- 44 people
- Sponsor
- Fate Therapeutics
Gastric Cancer, Colon Cancer
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
This is a phase I clinical study to evaluate the safety and tolerability of CAR-T in patients with CEA-positive advanced/metastatic solid tumors, and to obtain the maximum tolerated dose of CAR-T and phase II Recommended dose.
- Conditions
- Gastric Cancer, Colon Cancer, Pancreas Cancer, Esophagus Cancer
- Trial name
- NCT06010862
- Testing
- CEA CAR-T cells
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Advanced Colorectal Carcinoma
4SC-201 (Resminostat) in Advanced Colorectal Carcinoma
The purpose of this study is to determine the Maximum Tolerated Dose (MTD) of 4SC-201 (Resminostat) in combination with FOLFIRI and whether 4SC-201 (Resminostat) is effective and safe in combination FOLFIRI versus FOLFIRI alone…
- Trial name
- SHORE (NCT01277406)
- Testing
- 4SC-201(Resminostat), FOLFIRI
- Where
- 3 sites in Germany
- Volunteers
- 17 people
- Sponsor
- 4SC AG
Stomach Neoplasms
Biweekly Docetaxel in Combination With Capecitabine as First-Line Treatment in Patients With Advanced Gastric Cancer
To determine the quality of life in patients with gastric cancer who receive combination treatment with docetaxel and capecitabine. Secondary endpoints are time to progression, overall response rate and overall survival.
- Trial name
- GAST-TaxXel (NCT00669370)
- Testing
- docetaxel and capecitabine
- Where
- 6 sites in Finland
- Volunteers
- 50 people
- Sponsor
- University of Turku
Solid Tumor
Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer
Phase 1 study to evaluate the safety and tolerability of selinexor and determine the Recommended Phase 2 Dose (RP2D) of selinexor for advanced or metastatic solid tumor malignancies.
- Trial name
- NCT01607905
- Testing
- Selinexor, Acetaminophen
- Where
- 6 sites in United States, Canada and 1 more
- Volunteers
- 192 people
- Sponsor
- Karyopharm Therapeutics Inc
Melanoma, Thyroid Cancer
Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.
The study objective is to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of orally administered PLX8394 in patients with advanced solid tumors.
- Conditions
- Melanoma, Thyroid Cancer, Colorectal Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT02012231
- Testing
- PLX8394
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Fore Biotherapeutics
Gastric Carcinoma, Gastric Neoplasm
The Correlation Between Blood Concentration of Sintilimab and Efficacy and Adverse Reactions in Patients with Advanced Gastric Cancer
Compared with other anti-tumor drugs, immune checkpoint inhibitors (ICIs) have their own unique pharmacokinetics (PK) and pharmacodynamics (PD), and affect patient clinical outcomes.
- Conditions
- Gastric Carcinoma, Gastric Neoplasm, Gastric (cardia, Body) Cancer, Gastric Cancer Adenocarcinoma Metastatic
- Trial name
- NCT06702683
- Where
- China
- Volunteers
- 112 people
- Sponsor
- Lin Liu
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot be Removed by Surgery
This clinical trial studies radiolabeled glass beads (yttrium Y 90 glass microspheres) in treating patients with unresectable hepatocellular carcinoma.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT02072356
- Testing
- yttrium Y 90 glass microspheres, laboratory biomarker analysis, TheraSphere
- Where
- United States
- Volunteers
- 290 people
- Sponsor
- Ohio State University Comprehensive Cancer Center